# IFM 2009 (NCT01191060)

> Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: transplant-eligible newly diagnosed multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01191060
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: University Hospital, Toulouse
- Conditions: Myeloma
- Interventions: Lenalidomide, Bortezomib; Lenalidomide, Bortezomib
- Enrollment: 700
- Primary outcome: Progression Free Survival

## Indexed commentary on IFM 2009 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 72
- YouTube: 27
- Podcasts: 17

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ifm-2009-nct01191060

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01191060", "email": "<work email>"}; the inbox owner confirms by the emailed link.